Doesn't suck at all, and financials were as to be expected and gearing up nicely for Talicia launch.
Their R&D expenses have been dramatically reduced due to completing the Talicia Phase III, but marketing/sales and Admin expenses are up due to gearing for launch, which would be worrisome if this were not the case.
The sales of current marketed drugs on their list aren't going to wow anyone, and I don't think any of us are in this stock because of those.
They have probably about 55 million in the bank as of now and at current expenses will last them 5 quarters (4 quarters from Talicia planned launch) which should hopefully allow good traction to take hold on Talicia. Also will be interesting to see how the new Aemcolo performs for revenues.
Doesn't suck at all and indeed very believable.
Let's see what tomorrow's Talicia and Aemcolo marketing strategy call holds.
News 
Market Data 
Discover 
